Poxel Overview

  • Founded
  • 2009
Founded
  • Status
  • Public
  • Employees
  • 51
Employees
  • Stock Symbol
  • POXEL
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $8.54
  • (As of Thursday Closing)

Poxel General Information

Description

Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH). It has developed a portfolio of drug candidates, including its three most advanced candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Commercial Services
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • Immeuble Le Sunway
  • 259-261 Avenue Jean Jaurès
  • 69007 Lyon
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Poxel Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.54 $9.13 $6.71 - $10.40 $244M 28.6M 84K -$1.32

Poxel Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 190,736 190,736 308,789 33,772
Revenue 7,758 7,758 29,729 73,613
EBITDA (34,197) (34,197) (28,294) 1,298
Net Income (36,315) (36,315) (28,818) 1,535
Total Assets 80,043 80,043 80,991 120,700
Total Debt 29,054 29,054 8,555 15,619
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Poxel Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Poxel‘s full profile, request access.

Request a free trial

Poxel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, in
Other Commercial Services
Lyon, France
51 As of 2020
00000
000000000 00000

00000000

veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aut
0000000000000
South San Francisco, CA
00000 As of 0000
000.00
0000 0000-00-00
00000000000

00000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000000000000
Tübingen, Germany
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Poxel Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genentech Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
00000000 Formerly VC-backed Tübingen, Germany 000 00000 000000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000&0
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
0000000000 0000000 Corporation Ingelheim am Rhein, Germany 00000
You’re viewing 5 of 8 competitors. Get the full list »

Poxel Executive Team (11)

Name Title Board Seat Contact Info
Thomas Kuhn Co-Founder and Chief Executive Officer
Anne Renevot Chief Financial Officer
Sebastien Bolze Ph.D Chief Operating Officer, Founder and Executive Vice President
Quentin Durand Chief Legal Officer
David Moller MD Chief Scientific Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Poxel Board Members (6)

Name Representing Role Since
Khoso Baluch Self Board Member 000 0000
You’re viewing 1 of 6 board members. Get the full list »

Poxel Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Poxel Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Poxel‘s full profile, request access.

Request a free trial

Poxel Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 (000-000 0 30-Aug-2018 000000000 00000 00 000.00 Buildings and Property 000000 0000
To view Poxel’s complete investments history, request access »